MedTrace Logo

Study on the Safety and Efficacy of PA9159 Inhalation Aerosol for the Treatment of Adult Bronchial Asthma

NCT07324707 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-01-07

No results posted yet for this study

Summary

PA9159 is a highly potent novel corticosteroid. The purpose of this study is to evaluate the safety, efficacy and characteristics of population pharmacokinetics of multiple dosing of PA9159 Inhaler in patients with bronchial asthma.

Conditions

  • Bronchial Asthma

Interventions

DRUG

PA9159 Metered-Dose Inhaler, 120 μg per day for 28 days

PA9159 of 120 μg is delivered orally through a metered-dose Inhaler , Twice daily for 28 days.

DRUG

Fluticasone Propionate Inhaled Aerosol 200 μg per day for 28 days

Fluticasone Propionate Inhaled Aerosol of 200 μg is delivered orally through a metered-dose Inhaler , Twice daily for 28 days.

Sponsors & Collaborators

  • Anhui Palo Alto Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Wei Zuo · The First Affiliated Hospital of Nanchang University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-15
Primary Completion
2026-03-31
Completion
2026-03-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07324707 on ClinicalTrials.gov